ClinicalTrials.gg
RecruitingNCT06248411Updated May 27, 2026

A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of KK2260 and KK2260 in Advanced or Metastatic Solid Tumors, sponsored by Kyowa Kirin Co., Ltd.. Recruiting at 14 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by Kyowa Kirin Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
189
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is the first in human study of KK2260. In Part 1a, the maximum tolerated dose (MTD) will be determined while evaluating the safety and tolerability of KK2260 in patients with advanced or metastatic solid tumors (any cancer type). In Part 1b and Part 2, at least two dosing regimens and two dosing regimens by cancer type, respectively, will be selected, and the safety, tolerability, and efficacy of each regimen will be evaluated.

02

Conditions studied

  • Advanced or Metastatic Solid Tumors
03

In context

Lead sponsor

Kyowa Kirin Co., Ltd. is the lead sponsor of 159 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

\<Common Inclusion Criteria for Part 1a, Part 1b, and Part 2

  1. Patients who have given informed written consent.
  2. Male or female subjects ≥18 years of age, at time of signing .
  3. Subjects who are to standard treatment, intolerant of standard treatment, for whom standard treatment does not exist, or who have refused standard treatment.
  4. Patients with according to version 1.1
  5. Patients who have had the certaion periods between the date of completion of prior therapy and the date of enrollment
  6. Subjects who agree to have a tumor as part of the baseline examination. Patients who have difficulty in performing a tumour biopsy and have agreed to submit a previously collected stored specimen.
  7. Patients with an PS of 0 or 1 at baseline.
  8. Patients with haematopoietic, hepatic, renal, cardiac and respiratory functions that meet certain criteria in a baseline test.

\<Additional Inclusion Criteria for Part 1a

1) Patients with diagnosed advanced or solid tumors.

\<Additional Inclusion Criteria for Part 1b

  1. Patients with pathologically diagnosed with advanced or metastatic esophageal cancer, or advanced or metastatic head and neck cancer whose primary site of origin is the oral cavity, oropharynx, hypopharynx, larynx, nasal cavity, or paranasal sinuses.
  2. Patients with pathologically diagnosed squamous cell carcinoma.
  3. Patients who agree to undergo tumor biopsy after administration.

\<Additional Inclusion Criteria for Part 2a

  1. Patients with pathologically diagnosed with advanced or metastatic esophageal cancer.
  2. Patients with pathologically diagnosed squamous cell carcinoma.
  3. Patients who agree to undergo tumor biopsy after administration.

\<Additional Inclusion Criteria for Part 2b

  1. Patients with advanced or metastatic head and neck cancer whose primary site of origin is the oral cavity, oropharynx, hypopharynx, larynx, nasal cavity, or paranasal sinuses.
  2. Patients with pathologically diagnosed squamous cell carcinoma.
  3. Patients who agree to undergo tumor biopsy after administration.

Exclusion criteria

Exclusion Criteria:

\<Common Exclusion Criteria to Part 1 and Part 2>

  1. Patients with central or brain pia mater that are untreated and symptomatic or that require treatment.
  2. Patients with concurrent multiple or synchronous cancers, or with iatrogenic multiple or synchronous cancers with a disease-free interval of 5 years or less.
  3. Patients receiving continuous systemic administration of or other drugs.
  4. Patients who have had a Grade 3 or higher allergic reaction to an antibody agent or an additive of the study drug.
  5. Patients who have not recovered to Grade 1 or below from adverse events caused by previously administered anticancer therapy.
  6. Patients with active interstitial lung disease or a history of active interstitial lung disease.
  7. Patients with infectious diseases requiring systemic treatment.
  8. Patients with a fever of 38.0°C or higher at the time of registration.
  9. Patients who test positive for virus antigen or antibody, virus antibody, or antibody in a baseline test.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
189 participants (estimated)

Study arms

  • Experimental
    KK2260 (Dosing regimen 1)

    Drug: KK2260

  • Experimental
    KK2260 (Dosing regimen 2)

    Drug: KK2260

Interventions

  • DrugKK2260

    KK2260 will be administered intravenously at several dose levels, and after determining MTD, multiple dose regimens will be evaluated in multiple cancer types to target.

  • DrugKK2260

    KK2260 will be administered intravenously at several dose levels, and after determining MTD, multiple dose regimens will be evaluated in multiple cancer types to target.

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity (Only in Part 1a)

    Time frame: During the first cycle (1 Cycle = 28 days)

  2. Adverse Events

    Time frame: Through study completion, an average of 1 year

  3. Changes in Laboratory Testing Values (Red blood cell count)

    Time frame: Every week through study completion, an average of 1 year

  4. Changes in Laboratory Testing Values (Hemoglobin concentration)

    Time frame: Every week through study completion, an average of 1 year

  5. Changes in Laboratory Testing Values (Hematocrit)

    Time frame: Every week through study completion, an average of 1 year

  6. Changes in Laboratory Testing Values (Reticulocyte)

    Time frame: Every week through study completion, an average of 1 year

  7. Changes in Laboratory Testing Values (Mean corpuscular volume)

    Time frame: Every week through study completion, an average of 1 year

  8. Changes in Laboratory Testing Values (Mean corpuscular hemoglobin)

    Time frame: Every week through study completion, an average of 1 year

  9. Changes in Laboratory Testing Values (Mean corpuscular hemoglobin concentration)

    Time frame: Every week through study completion, an average of 1 year

  10. Changes in Laboratory Testing Values (White blood cell count)

    Time frame: Every week through study completion, an average of 1 year

  11. Changes in Laboratory Testing Values (Differential white blood cells (basophils, eosinophils, lymphocytes, monocytes, neutrophils))

    Time frame: Every week through study completion, an average of 1 year

  12. Changes in Laboratory Testing Values (Platelet count)

    Time frame: Every week through study completion, an average of 1 year

  13. Changes in Laboratory Testing Values (Total protein)

    Time frame: Every week through study completion, an average of 1 year

  14. Changes in Laboratory Testing Values (Albumin)

    Time frame: Every week through study completion, an average of 1 year

  15. Changes in Laboratory Testing Values (Alkaline phosphatase)

    Time frame: Every week through study completion, an average of 1 year

  16. Changes in Laboratory Testing Values (Alanine aminotransferase/Aspartate aminotransferase)

    Time frame: Every week through study completion, an average of 1 year

  17. Changes in Laboratory Testing Values (Total bilirubin/Direct bilirubin)

    Time frame: Every week through study completion, an average of 1 year

  18. Changes in Laboratory Testing Values (Blood urea nitrogen)

    Time frame: Every week through study completion, an average of 1 year

  19. Changes in Laboratory Testing Values (Calcium/Corrected Calcium)

    Time frame: Every week through study completion, an average of 1 year

  20. Changes in Laboratory Testing Values (Chloride)

    Time frame: Every week through study completion, an average of 1 year

  21. Changes in Laboratory Testing Values (Potassium)

    Time frame: Every week through study completion, an average of 1 year

  22. Changes in Laboratory Testing Values (Sodium)

    Time frame: Every week through study completion, an average of 1 year

  23. Changes in Laboratory Testing Values (Magnesium)

    Time frame: Every week through study completion, an average of 1 year

  24. Changes in Laboratory Testing Values (Serum iron)

    Time frame: Every week through study completion, an average of 1 year

  25. Changes in Laboratory Testing Values (Ferritin)

    Time frame: Every week through study completion, an average of 1 year

  26. Changes in Laboratory Testing Values (Total iron binding capacity)

    Time frame: Every week through study completion, an average of 1 year

  27. Changes in Laboratory Testing Values (Unsaturated iron binding capacity)

    Time frame: Every week through study completion, an average of 1 year

  28. Changes in Laboratory Testing Values (Serum creatinine)

    Time frame: Every week through study completion, an average of 1 year

  29. Changes in Laboratory Testing Values (Creatinine clearance (Cockcroft-Gault formula))

    Time frame: Every week through study completion, an average of 1 year

  30. Changes in Laboratory Testing Values (Lactate dehydrogenase)

    Time frame: Every week through study completion, an average of 1 year

  31. Changes in Laboratory Testing Values (Blood glucose)

    Time frame: Every week through study completion, an average of 1 year

  32. Changes in Laboratory Testing Values (Uric acid)

    Time frame: Every week through study completion, an average of 1 year

  33. Changes in Laboratory Testing Values (Lipase)

    Time frame: Every week through study completion, an average of 1 year

  34. Changes in Laboratory Testing Values (Amylase)

    Time frame: Every week through study completion, an average of 1 year

  35. Changes in Laboratory Testing Values (C-reactive protein)

    Time frame: Every week through study completion, an average of 1 year

  36. Changes in Laboratory Testing Values (Gamma-glutamyl transpeptidase)

    Time frame: Every week through study completion, an average of 1 year

  37. Changes in Laboratory Testing Values (Triglycerides)

    Time frame: Every week through study completion, an average of 1 year

  38. Changes in Laboratory Testing Values (Cholesterol)

    Time frame: Every week through study completion, an average of 1 year

  39. Changes in Laboratory Testing Values (Creatine phosphokinase)

    Time frame: Every week through study completion, an average of 1 year

  40. Changes in Laboratory Testing Values (Coagulation test)

    Prothrombin time international normalized ratio and Activated partial thromboplastin time

    Time frame: Every week through study completion, an average of 1 year

  41. Changes in Laboratory Testing Values (Hepatitis B virus DNA, if needed)

    Time frame: Every 2 cycle through study completion, an average of 1 year (1 Cycle = 28 days)

  42. Changes in Body temperature (degree Celsius)

    Time frame: Every week through study completion, an average of 1 year

  43. Changes in Systolic and Diastolic Blood Pressure (mmHg)

    Time frame: Every week through study completion, an average of 1 year

  44. Changes in SpO2 (%)

    Time frame: Every week through study completion, an average of 1 year

  45. Changes in Electrocardiogram parameters (Heart rate, PR interval, QRS interval, QT interval, and QTc intervals)

    The resting Heart rate, PR interval, QRS interval, QT interval, and QTc intervals will be recorded. Any abnormalities in ECG will be specified and documented as clinically significant or not clinically significant.

    Time frame: Every week through study completion, an average of 1 year

  46. Changes in Eastern Cooperative Oncology Group Performance Status (ECOG PS) (The score should be 0 to 4, and the lower is the better.)

    Time frame: Every week through study completion, an average of 1 year

Secondary outcomes

  1. Serum concentration levels of KK2260

    Time frame: Pre-dose and post-dose at multiple timepoints for each cycle during the intervention (each cycle is 28 days)

  2. Maximum Plasma Concentration (Cmax)

    Time frame: Pre-dose and post-dose at multiple timepoints for each cycle during the intervention (each cycle is 28 days)

  3. Area Under the blood concentration-time Curve (AUC)

    Time frame: Pre-dose and post-dose at multiple timepoints for each cycle during the intervention (each cycle is 28 days)

  4. Anti-drug antibody

    Time frame: Pre-dose and post-dose at multiple timepoints for each cycle during the intervention (each cycle is 28 days)

  5. Overall Response Rate (in Part 1b/2)

    Time frame: During the treatment and every 12 weeks after study treatment completion (approximately up to 1 year)

  6. Disease Control Rate (in Part 1b/2)

    Time frame: During the treatment and every 12 weeks after study treatment completion (approximately up to 1 year)

  7. Duration of Response (in Part 1b/2)

    Time frame: During the treatment and every 12 weeks after study treatment completion (approximately up to 1 year)

  8. Progression-Free Survival (in Part 1b/2)

    Time frame: During the treatment and every 12 weeks after study treatment completion (approximately up to 1 year)

  9. Overall Survival (in Part 1b/2)

    Time frame: During the treatment and every 12 weeks after study treatment completion (approximately up to 1 year)

  10. Time to Response (in Part 1b/2)

    Time frame: During the treatment and every 12 weeks after study treatment completion (approximately up to 1 year)

07

Study locations

14 of 14 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The datasets generated and/or analyzed during the study sponsored by Kyowa Kirin will be available in the Vivli repository, https://vivli.org/ourmember/kyowa-kirin/ as long as conditions of data disclosure specified in the policy section of the Vivli website are satisfied.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2023 (actual). Primary completion is estimated for Oct 2029, 71 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2023
First posted
Feb 8, 2024
StartActual
Nov 1, 2023
Primary completionEst.
Oct 31, 2029
CompletionEst.
Apr 30, 2030
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06248411
Responsible party
Sponsor
First posted
Feb 8, 2024
Start date
Nov 1, 2023
Primary completion
Oct 31, 2029 (estimated)
Completion
Apr 30, 2030 (estimated)
Last update
May 27, 2026

Study contacts

Kyowa Kirin Co., Ltd.
Contact
clinical.info.jp@kyowakirin.com
+81-3-5205-7200

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion